ArticlePloS one2025
Recurrent venous thromboembolism and clot distribution in COVID-19 infection: A review by variant type.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
research questionDo PE distribution and rates of recurrent VTE differ between COVID-19 (CAPE) and non-COVID-19 (NCAPE) patients and among COVID-19 variants? STUDY DESIGN AND
methodsA single-center retrospective chart review of 547 patients with PE admitted from January 2020-October 2022 was conducted. 470 patients did not have COVID-19 infection on admission. 77 patients had COVID-19 infection with 17, 27, and 33 admissions occurring during Alpha, Delta, and Omicron predominance, respectively. Imaging reports, follow-up, and recurrent VTE incidence were extracted. Central clot was defined as saddle or mainstem PE. Clot distribution was classified as central, peripheral, or both. Recurrent VTE was examined at 3 and 6 months.
resultsNCAPE and CAPE patients had similar patterns of clot distribution overall (P = 0.34, 0.48, & 0.82 for central, peripheral, and both, respectively). Of CAPE patients with solely peripheral PE distribution (N = 49), Omicron comprised 78.8% (N = 26, P = 0.01). Recurrent VTE occurred in 45 patients. The cumulative proportion of recurrent VTE or death did not differ significantly by COVID-19 status (P = 0.12).
conclusionsCOVID-19 infection is associated with VTE events which appear to vary in frequency and location among the different variants (Alpha, Omicron, and Delta).VTE risk is highest in the 3 months following COVID-19 infection.Recurrent rate of VTE is similar between patients with COVID-19-associated and non-COVID-19-associated PE.The VTE risk and clot distribution of COVID-19 is evolving over the years as the virus becomes endemic in the United States and warrants further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.